MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

Search

Heron Therapeutics Inc

Închisă

SectorSănătate

1.49

Rezumat

Modificarea prețului

24h

Curent

Minim

1.45

Maxim

1.51

Indicatori cheie

By Trading Economics

Venit

-15M

-17M

Vânzări

1M

38M

Marjă de profit

-45.783

Angajați

122

EBITDA

-12M

-14M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+202.01% upside

Dividende

By Dow Jones

Următoarele câștiguri

26 feb. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

57M

273M

Deschiderea anterioară

1.49

Închiderea anterioară

1.49

Sentimentul știrilor

By Acuity

37%

63%

118 / 361 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Bearish Evidence

Heron Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

16 ian. 2026, 23:29 UTC

Acțiuni populare

Stocks to Watch: Atossa Therapeutics, Union Pacific

16 ian. 2026, 22:48 UTC

Achiziții, Fuziuni, Preluări

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- 2nd Update

16 ian. 2026, 22:43 UTC

Achiziții, Fuziuni, Preluări

Union Pacific: Additional Information Requested to Be Provided to Surface Transportation Board

16 ian. 2026, 22:22 UTC

Achiziții, Fuziuni, Preluări

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- Update

16 ian. 2026, 21:50 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Tech, Media & Telecom Roundup: Market Talk

16 ian. 2026, 21:50 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Auto & Transport Roundup: Market Talk

16 ian. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

16 ian. 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

16 ian. 2026, 21:48 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Union Pacific, Norfolk Southern Market Share Ruled as Faulty -- Market Talk

16 ian. 2026, 21:41 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Union Pacific, Norfolk Southern Deal Rejection Leaves Questions -- Market Talk

16 ian. 2026, 21:38 UTC

Achiziții, Fuziuni, Preluări

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- WSJ

16 ian. 2026, 21:30 UTC

Achiziții, Fuziuni, Preluări

STB: Union Pacific, Norfolk Southern Application Doesn't Include 'Projected Market Shares' as Required

16 ian. 2026, 21:30 UTC

Achiziții, Fuziuni, Preluări

STB: Union Pacific, Norfolk Southern Application Doesn't Include Certain Schedules, Documents Expressly Made Part of Merger Agreement

16 ian. 2026, 21:30 UTC

Achiziții, Fuziuni, Preluări

STB: Union Pacific, Norfolk Southern Application Doesn't Contain Certain Information Required by Regulations

16 ian. 2026, 21:30 UTC

Achiziții, Fuziuni, Preluări

STB: Application Rejected Without Prejudice to Union Pacific, Norfolk Southern Refiling Revised Application Remedying Deficiencies

16 ian. 2026, 21:30 UTC

Achiziții, Fuziuni, Preluări

Surface Transportation Board: Union Pacific, Norfolk Southern Major Merger Application Filed Dec. 19 Incomplete

16 ian. 2026, 20:44 UTC

Câștiguri

5 Takeaways From This Season's Wealth Management Earnings -- Barrons.com

16 ian. 2026, 20:42 UTC

Market Talk

Oil Futures Post Fourth Straight Weekly Gain -- Market Talk

16 ian. 2026, 20:28 UTC

Market Talk

U.S. Natural Gas Slips Ahead of Long Weekend -- Market Talk

16 ian. 2026, 19:12 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Netflix Could Comment on Structure of Warner Bid During 4Q Results -- Market Talk

16 ian. 2026, 18:53 UTC

Market Talk

Global Crude Supply Enough to Absorb Any Iran Disruption -- Market Talk

16 ian. 2026, 18:41 UTC

Market Talk

Netflix's Ad Business Seen as Primary Revenue Driver in 2026 -- Market Talk

16 ian. 2026, 18:31 UTC

Market Talk

U.S. Oil Rig Count Rises By 1 to 410 -- Market Talk

16 ian. 2026, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

16 ian. 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

16 ian. 2026, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

16 ian. 2026, 17:03 UTC

Market Talk

Global Equities Roundup: Market Talk

16 ian. 2026, 17:03 UTC

Market Talk

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

16 ian. 2026, 16:32 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Sanofi Needs Dealmaking to Offset Pipeline Disappointments -- Market Talk

16 ian. 2026, 16:20 UTC

Market Talk

Global Equities Roundup: Market Talk

Comparație

Modificare preț

Heron Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

202.01% sus

Prognoză pe 12 luni

Medie 4.5 USD  202.01%

Maxim 6 USD

Minim 3 USD

În baza a 4 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruHeron Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

4 ratings

4

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

2.0001 / 2.42Suport & Rezistență

Termen scurt

Bearish Evidence

Termen mediu

Bullish Evidence

Termen lung

Bullish Evidence

Sentiment

By Acuity

118 / 361 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.
help-icon Live chat